# American Vanguard Corp: Form 10-Q for the period ended Mar 31, 2023

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2023-05-10
- Accepted by EDGAR: May 9, 2023, 18:25 ET
- Period: 2023-03-31
- Accession: 0000950170-23-019911
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000095017023019911/avd-20230331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000095017023019911/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $124.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $86.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $38.5m | us-gaap:GrossProfit |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | $3.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-01-01 to 2023-03-31 | $1.7m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | −$361.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | $1.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 29,073,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | −$41.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 3 months, 2023-01-01 to 2023-03-31 | $851.0k | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months, 2023-01-01 to 2023-03-31 | $557.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-03-31 | $19.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $435.0m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $771.1m | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $260.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $396.1m | us-gaap:Liabilities |
| Long-term debt | at 2023-03-31 | $97.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2023-03-31 | $375.0m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 24,441 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Annual Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 3., Quantitative and Qualitative Disclosures about Market Risk, and Part II, Item 1A., Risk Factors, in this Quarterly Report on Form 10-Q.

Effective January 11, 2023, the Company includes warehousing, handling and outbound freight costs in cost of sales instead of operating expenses on its condensed consolidated statements of operations. The effects of the change in accounting have been retrospectively applied to all periods presented. The Company believes that the change in accounting is preferable as it aligns the Company’s classification of this warehousing, handling and outbound freight costs in such a way as to present operational management with a clearer vision of the operational performance by business unit. This accounting change also increases the comparability of the Company’s financial performance with its peer companies as most peer companies include warehousing, handling and outbound freight costs in cost of sales rather than operating expenses. As a result, this change is intended to help interested parties better understand the Company’s performance and facilitate comparisons with most of the Company’s peer companies. The change in accounting principle did not have any impact on operating income, net income and earnings per share. Please refer to note 12 to the condensed consolidated financial statements for further details.

### Overview of the Company’s Performance

Domestic crop sales, and therefore, the Company’s financial performance for the first quarter of 2023 declined in most material respects as compared to the comparable period in 2022. While the domestic farm economy remains strong, supply disruptions and delays in raws and intermediates compounds used to manufacture the Company’s leading corn soil insecticide, coupled with shifts in procurement timing for its herbicides, yielded significantly lower sales in its domestic crop business, as compared to this time last year. By contrast, both the domestic non-crop and international businesses recorded slightly higher sales for the period. With lower sales of the higher margin domestic crop business, the Company’s overall sales and profit performance were adversely affected. While operating expenses declined, factory costs rose primarily as a result of not having the raw materials available to manufacture the corn soil insecticides products and as a result gross profit declined. Further, higher interest expenses (partially offset by lower tax expenses) yielded lower net income for the quarter, as compared to last year.

On a consolidated basis, domestic sales declined 25% while international rose by 2%, resulting in an overall net sales decline of 17%. Further, overall cost of sales, which has been subject to a change in definition to now incorporate the cost of outbound logistics and freight expenses, decreased by 12%. Cost of sales were 69% of sales in 2023, as compared to 66% for the same period of 2022. These factors, taken together with higher manufacturing costs (both labor and service-related), yielded a 25% decrease in gross profit (to $38,537 in 2023 from $51,395 in the comparable quarter of 2022), while overall gross margin percent declined to 31% from 34% quarter-over-quarter.

Operating expenses declined to $35,272 in Q1 2023 from $36,646; however, operating expenses as a percent of net sales rose to 28% in the first quarter of 2023 from 24% in the comparable period of 2022.

Operating income for the period decreased to $3,265 from $14,749, driven by the reduced sales, decreased gross margin percentage and proportionately higher operating expenses. The Company recorded higher interest expense due to federal interest rate increases during the intervening year. These factors yielded net income for the period of $1,918, as compared to $9,935 in the first quarter of 2022. Details on our financial performance are set forth below.

### RESULTS OF OPERATIONS

### Quarter Ended March 31:

| Net sales: | For the three months ended March 31, 2023 | 2022 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| U.S. crop | $61,876 | $88,193 | $(26,317) | -30% |
| U.S. non-crop | 13,899 | 13,396 | 503 | 4% |
| Total U.S. | 75,775 | 101,589 | (25,814) | -25% |
| International | 49,110 | 48,004 | 1,106 | 2% |
| Total net sales: | $124,885 | $149,593 | $(24,708) | -17% |
| Cost of sales: |  |  |  |  |
| U.S. crop | $41,254 | $54,200 | $(12,946) | -24% |
| U.S. non-crop | 8,453 | 7,629 | 824 | 11% |
| Total U.S. | 49,707 | 61,829 | (12,122) | -20% |
| International | 36,641 | 36,369 | 272 | 1% |
| Total cost of sales: | $86,348 | $98,198 | $(11,850) | -12% |
| Gross profit: |  |  |  |  |
| U.S. crop | $20,622 | $33,993 | $(13,371) | -39% |
| U.S. non-crop | 5,446 | 5,767 | (321) | -6% |
| Total U.S. | 26,068 | 39,760 | (13,692) | -34% |
| International | 12,469 | 11,635 | 834 | 7% |
| Total gross profit: | $38,537 | $51,395 | $(12,858) | -25% |
| Gross margin: |  |  |  |  |
| U.S. crop | 33% | 39% |  |  |
| U.S. non-crop | 39% | 43% |  |  |
| Total U.S. | 34% | 39% |  |  |
| International | 25% | 24% |  |  |
| Gross margin: | 31% | 34% |  |  |

Our **domestic crop business** recorded net sales during the first quarter of 2023 that were 30% lower than those of the first quarter of 2022 ($61,876 as compared to $88,193). Despite having taken extraordinary measures in the prior year to position suppliers in both the US and China, the Company experienced significant delays in obtaining critical intermediate compounds necessary to formulate our leading granular soil insecticide Aztec®. Ultimately, the Company was able to manufacture and sell only about one-third of the volume of Aztec as it had forecasted. Having already recorded strong sales of Counter® in fourth quarter of 2022, we worked with customers to place other alternative products during the first quarter of 2023 (i.e., Smartchoice®, Index® and Force®) and sold out of those products. Nevertheless, overall net sales of our corn soil insecticides were down about 45% compared to the first quarter of the prior year. In addition, sales of our Impact post-emergent corn herbicides, which (as they related to the wholesale distribution channel) were strong in the prior quarter, decreased in the first quarter due largely to higher-than-normal inventory levels of glyphosate and glufosinate (neither of which the Company sells) in the distribution channel. Further, procurement activity for Dacthal, a specialty crop herbicide, had shifted earlier (into the fourth quarter of 2022) than had been the case in the first quarter of 2022. This resulted in a nearly 40% decline in quarterly sales of our portfolio of herbicide products. By contrast, partially offsetting these declines, we saw a 30% increase in sales of our soil fumigants versus the prior year due in part to the gradual elimination of agricultural water allocation restrictions in California following abundant rainfall and record snowpack accumulation.

Cost of sales within the domestic crop business decreased by 24% (from $54,200 in 2022 to $41,254 in 2023) as a result of decreased volumes, as compared to the first quarter of 2022. In-bound freight costs rose due, in part, to our efforts to expedite shipment of intermediate compounds for Aztec production. Less favorable factory performance (arising from increased labor costs, higher service charges (at our Axis plant) and increased waste disposal charges (at our Los Angeles facility), coupled with lower factory absorption rates due to raw material supply delays that resulted in lower than expected output, led to a 35% decrease in gross profit for domestic crop (from $33,993 in 2022 to $20,622 in 2023).

Our **domestic non-crop business** posted a 4% increase in net sales in the first quarter 2023, as compared to the same period in the prior year ($13,899 in 2023 v. $13,396 in 2022). In this category, our Dibrom® mosquito adulticide generated steady sales compared to the same quarter of the prior year, as hurricane and tropical storm activity season were consistent with the prior year. Further, royalty and license fees for our Envance proprietary solutions were higher than the first quarter of last year. By contrast, we experienced lighter than normal demand for our commercial pest control products, including pest strips. In addition, we recorded slightly lower net sales from our OHP nursery and ornamental business and the pharmaceutical products of our GemChem business.

Cost of sales within the domestic non-crop business rose by about 11% in the first quarter 2023, as compared to the same period in the prior year (from $7,629 to $8,453). This was driven by a different mix of products including some lower margin products. With higher costs of sales on a concomitantly lower increase in net sales, gross profit for domestic non-crop decreased by 6% (from $5,767 in 2022 to $5,446 in 2023).

Net sales of our **international businesses** rose by about 2% during the period ($49,110 in 2023 vs. $48,004 in 2022). This group of businesses experienced increases in herbicides, fungicides, and plant growth regulators, partially offset by minor sales decreases in soil fumigants, foliar insecticides, and soil insecticides. We posted sales increases in the Central American market through our AgriCenter group (up 11%) and enjoyed improved demand for our Assure II herbicide in Canada. Our Australian business delivered higher sales and gross profits versus the prior year, as they focused on a more profitable product mix. Our performance in Mexico remained solid, despite temporary product importation impediments. By contrast, net sales of our business in Brazil declined due to general market inventories. Further, the international business of Agrinos, a key part of our Green Solutions platform, declined slightly in the quarter with lower sales in India and China, partially offset by a modest increase in Ukraine.

Cost of sales in our international business increased by 1% (from $36,369 in 2022 to $36,641 in 2023), which is consistent with the relative increase in net sales. Gross profit for the international businesses increased by about 7% (to $12,469 in 2023 from $11,635 in 2022), which was above the corresponding increase in net sales; the disparity was due largely to the shortage of high-value products produced by the Company domestically.

On a **consolidated basis,** gross profit for the first quarter of 2023 decreased by 25% (from $51,395 in 2022 to $38,537 in 2023). Decreased sales volume, unavailability of high-margin crop products and higher factory costs all factored into yielding reduced profitability. Overall gross margin percentage ended at 31% in the first quarter of 2023, as compared to 34% in the first quarter of the prior year.

Operating expenses decreased by $1,374 or 4% to $35,272 for the three months ended March 31, 2023, as compared to the same period in 2022. The differences in operating expenses by department are as follows:

|  | 2023 | 2022 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $13,371 | $11,243 | $2,128 | 19% |
| General and administrative |  |  |  |  |
| Other | 9,130 | 14,994 | (5,864) | -39% |
| Proxy activities | 541 | — | 541 | 100% |
| Amortization | 3,360 | 3,439 | (79) | -2% |
| Research, product development and regulatory | 8,870 | 6,970 | 1,900 | 27% |
|  | $35,272 | $36,646 | $(1,374) | -4% |

- Selling expenses increased by $2,128 for the three months ended March 31, 2023, as compared with the same period of the prior year. This included increased costs associated with employees and travel expenses as the business continues to grow and return to normal face to face contact with customers, and other costs supporting long term growth offset to a degree by the beneficial movements in some key exchange rates.
- General and administrative expenses decreased by $5,864 for the three months ended March 31, 2023, as compared to the same period of 2022. The main drivers were reduced short-term and long-term incentive compensation accruals that reflect the business performance for the first quarter of 2023, and benefits associated with favorable currency movements particularly in the Central America region.
- The Company spent $541 in fees associated with its proxy activities.
- Research, product development costs and regulatory expenses increased by $1,900 for the three months ended March 31, 2023, as compared to the same period of 2022. The main drivers were increased costs associated with the commercialization of our SIMPAS delivery system and costs associated with product defense and product development activities.

On April 1, 2020, the Company made a strategic investment in Clean Seed Inc., in the amount of $1,190. The Company recorded a negative fair value adjustment in the amount of $22 during the three months ended March 31, 2023, and a positive adjustment in the amount of $83 during the comparative three months of the prior year.

Interest costs net of capitalized interest were $1,686 in the first three months of 2023, as compared to $398 in the same period of 2022. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Q1 2023 Average Debt | Interest Expense | Interest Rate | Q1 2022 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $90,486 | $1,542 | 6.8% | $85,756 | $401 | 1.9% |
| Amortization of deferred loan fees | — | 63 | — | — | 69 | — |
| Amortization of other deferred liabilities | — | — | — | — | 6 | — |
| Other interest expense | 17,500 | 128 | 2.9% | — | 9 | — |
| Subtotal | $107,986 | $1,733 | 6.4% | $85,756 | $485 | 2.3% |
| Capitalized interest | — | (47) | — | — | (87) | — |
| Total | $107,986 | $1,686 | 6.2% | $85,756 | $398 | 1.9% |

The Company’s average overall debt for the three months ended March 31, 2023 was $90,486, as compared to $85,756 for the three months ended March 31, 2022. Our borrowings in the three months ended March 31, 2023 were higher when compared to the same period of the prior year, mainly as a result of increased working capital as the business worked through the logistics challenges related to Aztec. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 6.8% for the three months ended March 31, 2023, as compared to 1.9% in 2022.

Income tax benefit was $361 for the three months ended March 31, 2023, as compared to an income tax expense of $4,499 for the three-months ended March 31, 2022. The effective income tax rate for the three months ended March 31, 2023 was computed based on the estimated effective tax rate for the full year, adjusted for a benefit from the remeasurement of certain U.S. federal and state deferred taxes, partially offset by an expense attributed to establishing liabilities for uncertain tax positions in the U.S. and India. This calculation resulted in an effective tax rate of minus 23.2% for the three months ended March 31, 2023, as compared to 31.2% for the three months ended March 31, 2022.

It is expected that $1,550 of unrecognized tax benefits will be released within the next twelve months due to expiration of the statute of limitations.

Our overall net income for the first three months of 2023 was $1,918 or $0.07 per basic and diluted share, as compared to $9,935 or $0.33 per basic and diluted share in the first quarter of 2022.

### LIQUIDITY AND CAPITAL RESOURCES

The Company used cash of $41,447 in operating activities during the three months ended March 31, 2023, as compared to $32,315 during the three months ended March 31, 2022. Included in the $41,447 are net income of $1,918, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $6,253, provision for bad debts in the amount of $581 and other in the amount of $94. Also included are stock-based compensation of $1,474, decrease in deferred income taxes of $122, change in liabilities for uncertain tax positions or unrecognized tax benefits of $371, and net change in foreign currency adjustment of $446. These together provided net cash inflows of $10,367, as compared to $18,942 for the same period of 2022.

During the first three months of 2023, the Company increased net working capital by $52,995, as compared to $55,031 during the same period of the prior year. Included in this change: inventories increased by $33,731, as compared to $11,738 for the first quarter of 2022. Customer prepayments decreased by $22,759, as compared to $44,528 in the same period of 2022, driven by customer decisions regarding demand, payment timing and our cash incentive programs. Our accounts payable balances increased by $5,655, as compared to $9,677 in the same period of 2022. Accounts receivable increased by $8,779, as compared to $33,660 in the same period of 2022. Prepaid expenses decreased by $600, as compared to $800 in the same period of 2022. Income tax receivable increased by $2,965, as compared to a decrease of $3,046 in the prior year. Accrued programs increased by $10,660, as compared to $24,601 in the prior year, as a result of both higher sales and the mix of those sales including products with higher program elements incorporated in pricing. Finally, other payables and accrued expenses decreased by $500, as compared to an increase of $2,145 in the prior year.

With regard to our program accrual, the increase (as noted above) primarily reflects our level and mix of sales and customers in the first quarter of 2023, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first quarter of 2022, the Company made accruals for programs in the amount of $23,669 and made payments in the amount of $13,033. During the first quarter of the prior year, the Company made accruals in the amount of $40,469 and made payments in the amount of $15,752.

Cash used for investing activities was $3,308 for the three months ended March 31, 2023, as compared to $4,250 for the three months ended March 31, 2022. The Company spent $2,590 on fixed assets acquisitions primarily focused on continuing to invest in manufacturing infrastructure. In addition, the Company made a payment of $703 for a product acquisition and spent $15 on patents for the Envance technology business.

During the three months ended March 31, 2023, financing activities provided $43,777, as compared to $37,449 during the same period of the prior year. Net borrowings under the Credit Agreement amounted to $44,700 in the first quarter of 2023, as compared to $46,000 in the same period of the prior year. The Company paid dividends to stockholders amounting to $851 during the three months ended March 31, 2023, as compared to $594 in the same period of 2022. The Company paid $557 for the repurchase of 27,835 shares of its common stock during the three months ended March 31, 2023, as compared to $6,219 to purchase 332,404 shares in the same period of the prior year. The Company received $18 from the exercise of stock options. Lastly, in exchange for shares of common stock returned by employees, we paid $13 and $2,174 for tax withholding on stock-based compensation awards during the three months ended March 31, 2023 and 2022, respectively.

The Company’s main bank is Bank of the West, a wholly owned subsidiary of BMO Financial Group. Bank of the West has been the Company’s bank for more than 30 years and is the syndication manager for the Company’s revolving line of credit shown as long-term debt in the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022. The debt is summarized in the following table:

| Long-term indebtedness | March 31, 2023 | December 31, 2022 |
| --- | ---: | ---: |
| Revolving line of credit | $97,000 | $52,300 |
| Deferred loan fees | (761) | (823) |
| Total indebtedness | $96,239 | $51,477 |

As of March 31, 2023, the Company was in compliance with the Consolidated Funded Debt Ratio but noncompliant with respect to the Fixed Charge Covenant ratio (“FCCR”). The noncompliance was driven by a reduction in the Consolidated EBITDA (in the numerator of the FCCR calculation) during the twelve months ended March 31, 2023, coupled with higher-than-normal distributions (in the denominator of the FCCR calculation) arising from share repurchases made by the Company during the same period. On May 8, 2023, the Company obtained a waiver of the FCCR for the twelve months ended March 31, 2023, and an adjustment to the FCCR terms for the period ending June 30, 2023. The impact of most of the share repurchases will be eliminated from the denominator in the FCCR calculation in the third quarter of 2023.

At March 31, 2023, according to the terms of the Credit Agreement, as amended, and based on our performance against the most restrictive covenant listed above, the Company had the capacity to increase its borrowings by up to $111,922. This compares to an available borrowing capacity of $200,372 as of December 31, 2022.

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our amended senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 16 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued and adopted accounting standards.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2022, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2022.

Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the condensed consolidated financial statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.

## Market risk

As filed, 1,173 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2022.

The Company faces market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency as to foreign subsidiaries’ revenues, expenses, assets and liabilities. The Company currently does not engage in hedging activities with respect to such exchange rate risks.

Assets and liabilities outside the U.S. are located in regions where the Company has subsidiaries or joint ventures: Central America, South America, North America, Europe, Asia, and Australia. The Company’s investments in foreign subsidiaries and joint ventures with a functional currency other than the U.S. dollar are generally considered long-term. Accordingly, the Company does not hedge these net investments.

## Controls and procedures

As filed, 1,058 characters.

As of March 31, 2023, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of March 31, 2023, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, had concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 3,140 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 16, 2023. The following disclosure amends and supplements those risk factors and, except to the extent restated below, there are no material changes to the risk factors as so stated.

***Disruption in the global supply chain is creating delays, unavailability and adverse conditions for our industry—***Despite improvement in container availability and freight costs, the global supply chain continues to present risk. Industry consolidation, coupled with longer-term production commitments, has materially affected the Company’s supply of raws and intermediates in the past. There is no guarantee that the supply chain condition will materially improve any time soon or that the Company will continue to avoid material disruption. Such disruption could have a material adverse effect on the Company’s operations, financial condition or cash flows.

***The Company is dependent upon sole source or a limited number of suppliers for certain of its raw materials and active ingredients—***There are a limited number of suppliers of certain important raw materials used by the Company in a number of its products. Certain of these raw materials are available solely from single or very few sources either domestically or overseas. In connection with supply chain disruptions in 2022, phosphorus and related compounds were increasingly difficult to source for our entire industry; ensuring a continuous supply required extraordinary efforts both with respect to sourcing and production planning. That said, there is no guarantee that any of our suppliers will be willing or able to supply products to the Company reliably, continuously and at the levels anticipated by the Company or required by the market. If these sources prove to be unreliable and the Company is not able to supplant or otherwise second source these products, it is possible that the Company will not achieve its projected sales which, in turn, could adversely affect the Company's consolidated financial statements.

***The Company benefits from customer early pay in meeting its working capital needs.*** As is the case with other companies in this industry, the Company receives cash from certain major customers at year-end in exchange for granting discounts on the Company’s products during the first half of the following year. The Company typically uses this cash to pay down secured debt and for other working capital needs. This flow of cash obviates the need for additional borrowing, which, in turn, preserves borrowing capacity used in part for paying customer programs in the middle of the calendar year and, consequently, reduces interest expense. There is no guarantee that the Company’s customers will continue to support the early pay program at current levels. Further a material change in this program could have an adverse effect upon the Company’s liquidity and its ability to meet working capital demands.

Filed May 10, 2023.
Source: SEC EDGAR, the filing index for accession 0000950170-23-019911. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
